Companies / BDX

BCAL DIAGNOSTICS LIMITED

ASX:BDXPharmaceuticals, Biotechnology & Life Sciences
368.7M shares on issueASX (delayed) · as of 28 July 2026$0.071price · delayed$28.8Mmarket cap · indicative
C
Dilution grade

Runway under 2 quarters; 1 cash raise in 24 months; options/rights overhang 6% of shares

Cash runway-0.2 quarters of funding
Share-count growth (24m)3.2%
Raise cadence (24m)1 cash raise
Options & rights overhang6.4% of shares
In-the-money supply0.9% of shares
Pending proposed issuesnone

BCAL DIAGNOSTICS LIMITED's ordinary share count rose 3.2% between July 2024 and March 2026 to 369M shares. The company raised capital once in that period via a Convertible Note Facility dated October 2025 for A$10.0M, totaling A$10.0M of disclosed proceeds. Options and rights on issue could convert into 24M new shares, equal to 6.4% of the current share count, of which 1% are in the money; the nearest expiry is October 2026. At the March 2026 quarter the company reported available cash of A$-369K, representing -0.2 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
6.4%
Max option dilution
0.9%
ITM option dilution
1
Raises · last 12 months
-0.2 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 368.7M per ASX (delayed) (28 July 2026).
360.8M363.7M366.6MDec 24Sept 25July 26Cash raise · 21 Oct 2025

Cash runway

-0.2 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$-369k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
14 July 20263G · unquotedBDX : ORDINARY FULLY PAID368.7MAppendix 3G
14 July 20263G · unquotedBDX : ORDINARY FULLY PAID368.7MAppendix 3G
14 July 20263G · unquotedBDX : ORDINARY FULLY PAID368.7MAppendix 3G
14 July 20263G · unquotedBDX : ORDINARY FULLY PAID368.7MAppendix 3G
6 Mar 20262A · quoted issueBDX : ORDINARY FULLY PAID368.7MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$10.0M
Convertible Note Facility
21 Oct 2025 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

6.4%
Total overhang · of current shares
0.9%
In the money · at current price
23.6M
Potential new shares
Oct 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
19 Mar 2026Jayne ShawBuy225k2.0M$22k3Y notice
18 Mar 2026Jayne ShawBuy—2.0M$8k3Y notice
16 Mar 2026Jayne ShawBuy300k2.0M$29k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

14 July 2026Notification regarding unquoted securities - BDX
14 July 2026Notification regarding unquoted securities - BDX
14 July 2026Notification regarding unquoted securities - BDX
14 July 2026Notification regarding unquoted securities - BDX
2 July 2026$PBCAL to Acquire Shares in Genetic Signatures
28 June 2026$PBCAL Secures Funding for FY2027
17 June 2026$PBCAL Develops New Blood Test for Breast Cancer Recurrence
27 May 2026Validation Agreement Signed with Sonic USA, for Breastest V2
19 May 2026$PBCAL Launches Early Detection Cancer Platform
10 May 2026$PBCAL Appoints Anne-Louise Arnett as Chief Executive Officer
21 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
30 Mar 2026BCAL Submits MSAC Application for Avantect Pancreatic Test
25 Mar 2026$PBCAL Accelerates Rollout of Avantect Early Detection Tests
20 Mar 2026Change of Director's Interest Notice
19 Mar 2026Change of Director's Interest Notice
17 Mar 2026Change of Director's Interest Notice
6 Mar 2026Cleansing Notice
6 Mar 2026Application for quotation of securities - BDX
20 Feb 2026Change of Director's Interest Notice
18 Feb 2026BCAL Half Year Results Presentation December 2025

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.